267
Participants
Start Date
May 10, 2021
Primary Completion Date
June 24, 2023
Study Completion Date
June 24, 2023
Tirzepatide
Administered SC
Placebo
Administered SC
Saiseikai Yokohamashi Tobu Hospital, Yokohama
Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa
Saiseikai Matsuyama Hospital, Matsuyama
Takai Internal Medicine Clinic, Kamakura-shi
Motomachi Takatsuka Naika Clinic, Yokohama
Osaka Saiseikai Suita hospital, Suita
Medical Corporation Heishinkai OCROM Clinic, Suita-shi
Takatsuki Red Cross Hospital, Takatsuki
The Institute for Adult Disease, Asahi Life Foundation, Chuo-ku
Tokyo-Eki Center-building Clinic, Chuo-ku
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku
Fukuwa Clinic, Chuo-ku
Saiseikai Central Hospital, Minato-Ku
Shimokitazawa Tomo Clinic, Setagaya-ku
Miho Clinic, Shinagawa-ku
Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku
Yamagata Tokushukai Hospital, Yamagata
AMC Nishiumeda Clinic, Osaka
Eli Lilly and Company
INDUSTRY